









Markets
/
Stocks
/
nasdaq-espr
/

Esperion Therapeutics Inc

ESPR

3.400USD

+0.220+6.92%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

698.46MMarket Cap

LossP/E TTM



Esperion Therapeutics Inc

3.400

+0.220+6.92%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Esperion Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Esperion Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 71 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.47.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Esperion Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

71 / 159

Overall Ranking

186 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Esperion Therapeutics Inc Highlights

StrengthsRisks

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 340.30% year-on-year.

Undervalued

The company’s latest PE is -6.32, at a low 3-year percentile range.

Held by PRFDX

Star Investor PRFDX holds 20.29K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

6.473

Target Price

+103.54%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Esperion Therapeutics Inc is 8.09, ranking 86 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 87.31M, representing a year-over-year increase of 69.10%, while its net profit experienced a year-over-year increase of 6.13%.

Score

Industry at a Glance

Previous score

8.09

Change



Financials

5.61

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.19

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Esperion Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Esperion Therapeutics Inc is 7.58, ranking 62 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -6.32, which is -94.90% below the recent high of -0.32 and -33.92% above the recent low of -8.46.

Score

Industry at a Glance

Previous score

7.58

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 71/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Esperion Therapeutics Inc is 7.50, ranking 104 out of 159 in the Pharmaceuticals industry. The average price target is 4.50, with a high of 16.00 and a low of 1.72.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

6.473

Target Price

+103.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Esperion Therapeutics Inc

ESPR

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Esperion Therapeutics Inc is 7.42, ranking 56 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 3.97 and the support level at 2.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.05

Change

0.37

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.031

Neutral

RSI(14)

49.161

Neutral

STOCH(KDJ)(9,3,3)

48.103

Sell

ATR(14)

0.214

High Vlolatility

CCI(14)

22.252

Neutral

Williams %R

30.769

Buy

TRIX(12,20)

-0.313

Sell

StochRSI(14)

71.442

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

3.402

Sell

MA10

3.417

Sell

MA20

3.324

Buy

MA50

3.626

Sell

MA100

3.211

Buy

MA200

2.309

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Esperion Therapeutics Inc is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 64.59%, representing a quarter-over-quarter decrease of 15.83%. The largest institutional shareholder is The Vanguard, holding a total of 14.95M shares, representing 6.25% of shares outstanding, with 7.86% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

12.09M

+3.21%

BlackRock Institutional Trust Company, N.A.

13.47M

+0.15%

Two Seas Capital LP

9.75M

-2.06%

Wasatch Global Investors Inc

Star Investors

7.06M

-31.71%

PenderFund Capital Management, Ltd.

6.68M

Geode Capital Management, L.L.C.

4.75M

+3.65%

State Street Investment Management (US)

4.48M

+19.16%

Two Sigma Investments, LP

4.16M

+6.07%

Meditor Capital Management Limited

3.79M

Nuveen LLC

3.63M

+759.96%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Esperion Therapeutics Inc is 4.18, ranking 92 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Esperion Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.